Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of etrasimod in Japanese patients with moderately to severely active ulcerative colitis
jRCT2071210052Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of etrasimod in autoimmune colitis (3 arms), sponsored by Pfizer. Primary endpoint: Clinical remission at Week 12. Started Oct 2021; status: completed.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2071210052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210052.